Clinical Trial

Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare the efficacy and safety of ICP-332 to placebo in participants with moderate-to-severe plaque psoriasis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-19.
Status change: Not Yet Recruiting → Recruiting 2025-12-24
Trial Details
NCT Number NCT07251998
Lead Sponsor Beijing InnoCare Pharma Tech Co., Ltd.
Conditions Plaque Psoriasis
Enrollment 172 participants
Start Date 2025-12-22
Primary Completion 2026-10 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2025-12-31